Literature DB >> 26719247

Native Conformation and Canonical Disulfide Bond Formation Are Interlinked Properties of HIV-1 Env Glycoproteins.

Eden P Go1, Albert Cupo2, Rajesh Ringe2, Pavel Pugach2, John P Moore2, Heather Desaire3.   

Abstract

UNLABELLED: We investigated whether there is any association between a native-like conformation and the presence of only the canonical (i.e., native) disulfide bonds in the gp120 subunits of a soluble recombinant human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoprotein. We used a mass spectrometry (MS)-based method to map the disulfide bonds present in nonnative uncleaved gp140 proteins and native-like SOSIP.664 trimers based on the BG505 env gene. Our results show that uncleaved gp140 proteins were not homogeneous, in that substantial subpopulations (20 to 80%) contained aberrant disulfide bonds. In contrast, the gp120 subunits of the native-like SOSIP.664 trimer almost exclusively retained the canonical disulfide bond pattern. We also observed that the purification method could influence the proportion of an Env protein population that contained aberrant disulfide bonds. We infer that gp140 proteins may always contain a variable but substantial proportion of aberrant disulfide bonds but that the impact of this problem can be minimized via design and/or purification strategies that yield native-like trimers. The same factors may also be relevant to the production and purification of monomeric gp120 proteins that are free of aberrant disulfide bonds. IMPORTANCE: It is widely thought that a successful HIV-1 vaccine will include a recombinant form of the Env protein, a trimer located on the virion surface. To increase yield and simplify purification, Env proteins are often made in truncated, soluble forms. A consequence, however, can be the loss of the native conformation concomitant with the virion-associated trimer. Moreover, some soluble recombinant Env proteins contain aberrant disulfide bonds that are not expected to be present in the native trimer. To assess whether these observations are linked, to determine the extent of disulfide bond scrambling, and to understand why scrambling occurs, we determined the disulfide bond profiles of two soluble Env proteins with different designs that are being assessed as vaccine candidates. We found that uncleaved gp140 forms heterogeneous mixtures in which aberrant disulfide bonds abound. In contrast, BG505 SOSIP.664 trimers are more homogeneous, native-like entities that contain predominantly the native disulfide bond profile.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26719247      PMCID: PMC4810632          DOI: 10.1128/JVI.01953-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer.

Authors:  Dmitry Lyumkis; Jean-Philippe Julien; Natalia de Val; Albert Cupo; Clinton S Potter; Per-Johan Klasse; Dennis R Burton; Rogier W Sanders; John P Moore; Bridget Carragher; Ian A Wilson; Andrew B Ward
Journal:  Science       Date:  2013-10-31       Impact factor: 47.728

2.  Crystal structure of a soluble cleaved HIV-1 envelope trimer.

Authors:  Jean-Philippe Julien; Albert Cupo; Devin Sok; Robyn L Stanfield; Dmitry Lyumkis; Marc C Deller; Per-Johan Klasse; Dennis R Burton; Rogier W Sanders; John P Moore; Andrew B Ward; Ian A Wilson
Journal:  Science       Date:  2013-10-31       Impact factor: 47.728

3.  Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.

Authors:  Claudia Blattner; Jeong Hyun Lee; Kwinten Sliepen; Ronald Derking; Emilia Falkowska; Alba Torrents de la Peña; Albert Cupo; Jean-Philippe Julien; Marit van Gils; Peter S Lee; Wenjie Peng; James C Paulson; Pascal Poignard; Dennis R Burton; John P Moore; Rogier W Sanders; Ian A Wilson; Andrew B Ward
Journal:  Immunity       Date:  2014-04-24       Impact factor: 31.745

4.  A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140.

Authors:  Miklos Guttman; Kelly K Lee
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

5.  Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers.

Authors:  Laura K Pritchard; Snezana Vasiljevic; Gabriel Ozorowski; Gemma E Seabright; Albert Cupo; Rajesh Ringe; Helen J Kim; Rogier W Sanders; Katie J Doores; Dennis R Burton; Ian A Wilson; Andrew B Ward; John P Moore; Max Crispin
Journal:  Cell Rep       Date:  2015-06-04       Impact factor: 9.423

6.  Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation.

Authors:  Rajesh P Ringe; Rogier W Sanders; Anila Yasmeen; Helen J Kim; Jeong Hyun Lee; Albert Cupo; Jacob Korzun; Ronald Derking; Thijs van Montfort; Jean-Philippe Julien; Ian A Wilson; Per Johan Klasse; Andrew B Ward; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

7.  Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies.

Authors:  Nancy P Y Chung; Katie Matthews; Helen J Kim; Thomas J Ketas; Michael Golabek; Kevin de Los Reyes; Jacob Korzun; Anila Yasmeen; Rogier W Sanders; Per Johan Klasse; Ian A Wilson; Andrew B Ward; Andre J Marozsan; John P Moore; Albert Cupo
Journal:  Retrovirology       Date:  2014-04-25       Impact factor: 4.602

8.  Glycosylation and disulfide bond analysis of transiently and stably expressed clade C HIV-1 gp140 trimers in 293T cells identifies disulfide heterogeneity present in both proteins and differences in O-linked glycosylation.

Authors:  Eden P Go; David Hua; Heather Desaire
Journal:  J Proteome Res       Date:  2014-08-06       Impact factor: 4.466

9.  Structure and immune recognition of trimeric pre-fusion HIV-1 Env.

Authors:  Marie Pancera; Tongqing Zhou; Aliaksandr Druz; Ivelin S Georgiev; Cinque Soto; Jason Gorman; Jinghe Huang; Priyamvada Acharya; Gwo-Yu Chuang; Gilad Ofek; Guillaume B E Stewart-Jones; Jonathan Stuckey; Robert T Bailer; M Gordon Joyce; Mark K Louder; Nancy Tumba; Yongping Yang; Baoshan Zhang; Myron S Cohen; Barton F Haynes; John R Mascola; Lynn Morris; James B Munro; Scott C Blanchard; Walther Mothes; Mark Connors; Peter D Kwong
Journal:  Nature       Date:  2014-10-08       Impact factor: 49.962

10.  Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.

Authors:  Anila Yasmeen; Rajesh Ringe; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Dennis R Burton; Andrew B Ward; Ian A Wilson; Rogier W Sanders; John P Moore; Per Johan Klasse
Journal:  Retrovirology       Date:  2014-05-29       Impact factor: 4.602

View more
  21 in total

1.  Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies.

Authors:  Gilad Kaplan; Anna Roitburd-Berman; George K Lewis; Jonathan M Gershoni
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

2.  Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States.

Authors:  Jeremiah D Heredia; Jihye Park; Hannah Choi; Kevin S Gill; Erik Procko
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

Review 3.  Recent mass spectrometry-based techniques and considerations for disulfide bond characterization in proteins.

Authors:  Jude C Lakbub; Joshua T Shipman; Heather Desaire
Journal:  Anal Bioanal Chem       Date:  2017-12-18       Impact factor: 4.142

Review 4.  Harnessing post-translational modifications for next-generation HIV immunogens.

Authors:  Joel D Allen; Rogier W Sanders; Katie J Doores; Max Crispin
Journal:  Biochem Soc Trans       Date:  2018-05-21       Impact factor: 5.407

5.  Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer.

Authors:  Anna-Janina Behrens; David J Harvey; Emilia Milne; Albert Cupo; Abhinav Kumar; Nicole Zitzmann; Weston B Struwe; John P Moore; Max Crispin
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

6.  Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.

Authors:  Eden P Go; Haitao Ding; Shijian Zhang; Rajesh P Ringe; Nathan Nicely; David Hua; Robert T Steinbock; Michael Golabek; James Alin; S Munir Alam; Albert Cupo; Barton F Haynes; John C Kappes; John P Moore; Joseph G Sodroski; Heather Desaire
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

7.  Disulfide Bond Characterization of Endogenous IgG3 Monoclonal Antibodies Using LC-MS: An Investigation of IgG3 Disulfide-mediated Isoforms.

Authors:  Jude C Lakbub; Daniel F Clark; Ishan S Shah; Zhikai Zhu; Eden P Go; Thomas J Tolbert; Heather Desaire
Journal:  Anal Methods       Date:  2016-07-27       Impact factor: 2.896

8.  Dual Pathways of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trafficking Modulate the Selective Exclusion of Uncleaved Oligomers from Virions.

Authors:  Shijian Zhang; Hanh T Nguyen; Haitao Ding; Jia Wang; Shitao Zou; Lihong Liu; Debjani Guha; Dana Gabuzda; David D Ho; John C Kappes; Joseph Sodroski
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

9.  Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages.

Authors:  Anna-Janina Behrens; Abhinav Kumar; Max Medina-Ramirez; Albert Cupo; Kevin Marshall; Victor M Cruz Portillo; David J Harvey; Gabriel Ozorowski; Nicole Zitzmann; Ian A Wilson; Andrew B Ward; Weston B Struwe; John P Moore; Rogier W Sanders; Max Crispin
Journal:  J Proteome Res       Date:  2018-02-08       Impact factor: 4.466

Review 10.  Quantitative clinical glycomics strategies: A guide for selecting the best analysis approach.

Authors:  Milani W Patabandige; Leah D Pfeifer; Hanna T Nguyen; Heather Desaire
Journal:  Mass Spectrom Rev       Date:  2021-02-10       Impact factor: 9.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.